Immune checkpoint inhibition for pancreatic ductal adenocarcinoma: limitations and prospects: a systematic review
Abstract Pancreatic cancer is an extremely malignant tumor with the lowest 5-year survival rate among all tumors. Pancreatic ductal adenocarcinoma (PDAC), as the most common pathological subtype of pancreatic cancer, usually has poor therapeutic results. Immune checkpoint inhibitors (ICIs) can relie...
Guardado en:
Autores principales: | Hong-Bo Li, Zi-Han Yang, Qing-Qu Guo |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
BMC
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/406634dabe0244e6958f3f3e3ac6d2be |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Advances in Pancreatic Ductal Adenocarcinoma Treatment
por: Eric M. Anderson, et al.
Publicado: (2021) -
Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma
por: Iranzu González-Borja, et al.
Publicado: (2021) -
Radiation combines with immune checkpoint blockade to enhance T cell priming in a murine model of poorly immunogenic pancreatic cancer
por: Courtney T. Stump, et al.
Publicado: (2021) -
CCL2 produced by pancreatic ductal adenocarcinoma is essential for the accumulation and activation of monocytic myeloid‐derived suppressor cells
por: Haitao Gu, et al.
Publicado: (2021) -
Epithelial to Mesenchymal Transition: Key Regulator of Pancreatic Ductal Adenocarcinoma Progression and Chemoresistance
por: Kostas Palamaris, et al.
Publicado: (2021)